Mechanistic models and hypothesis-driven strategies generate optimized efficient solutions for drug development, says ...

Quality, stability, sustainability, and the increased and thoughtful integration of artificial intelligence are foremost in the minds of those on the leading edge of testing trends.

Robust scale-down agitation models simulate mechanical stress essential for assessing and preventing protein aggregation in ...

The FDA's CNPV program accelerates product reviews to two months for national priority products, enhancing market entry speed ...

At AAPS PharmSci 360 2025, held from Nov. 9–12 in San Antonio, Texas, Corey Bloom, PhD, associate director, CMC (chemistry, ...

A streamlined workflow using Six Sigma's DMAIC methodology was developed to identify and mitigate visible particles in ...

Thermo Fisher’s Jennifer Cannon reviews the first year of the company’s Accelerator Drug Development suite of services and ...

In the life sciences industry, the journey from discovery to delivery is only as strong as the supply chain and distribution ...

Steve will be monitoring the Rapid Fires: AI/ML in Bioanalysis session on Monday, Nov. 10, 2025 at 3PM CT at AAPS PharmSci ...

A worldwide, exclusive license is being granted to develop and commercialize enzyme replacement therapies using proprietary platform technology.

To prevent catastrophic loss of expertise and investment, government and academic leaders say coordinated policy and significant investment in workforce talent are urgently needed in the UK.

At AAPS PharmSci 360 2025, Elly Zhou says digital twins helped forecast the effects of drugs on human drugs via a digital control arm.